Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION Drug Costs Should Be Basically Borne by Patients under Compassionate Use System: JPMA’s Kuwahara
December 5, 2012
-
ORGANIZATION 80 Medical Institutions Submit Comprehensive Agreements on Info Disclosure in Response to JPMA Transparency GLs
December 4, 2012
-
REGULATORY MHLW to Conduct Field Study for Japanese Version of “Compassionate Use” System
December 3, 2012
-
BUSINESS Fast-growing Plavix Could Become Japan’s No. 1 Ethical Drug by Next Year
December 3, 2012
-
BUSINESS CMIC MPSS to Offer Comprehensive Region-Wide CSO Service for Long-Listed Drugs
November 30, 2012
-
REGULATORY FPMAJ Chairman Naito Nudges CSIMC to Discuss Perpetuation of Premiums, Abolishment of Special Price Cuts for Long-Listed Drugs
November 29, 2012
-
ORGANIZATION IGPA Annual Conference to Adopt Kyoto Declaration including Int’l Harmonization on Generic Evaluation Criteria
November 28, 2012
-
BUSINESS Bayer Eyes Sales of €3 Billion in Japan by 2017: Chairman Dekkers
November 27, 2012
-
BUSINESS Health Professionals Voice Concerns over JPMA Transparency Guidelines
November 26, 2012
-
BUSINESS Decline in Sales of Long-listed Drugs Continues with a Double-punch from Generics, NHI Price Reductions
November 26, 2012
-
BUSINESS MSD to Promote Joint Detailing by Sales Units Specialized in Different Therapeutic Fields: Vice Pres. Kotani
November 22, 2012
-
REGULATORY MHLW Set to Clarify Review Procedures for Companion Diagnostics
November 21, 2012
-
REGULATORY GRU to Propose that Welfare Beneficiaries Be Required to Use Generics as a Rule
November 20, 2012
-
BUSINESS Novartis to Revamp Marketing Structure in CNS Field, Shift from SOV
November 19, 2012
-
BUSINESS E Keppra Grabs 20% Share of Domestic Anti-Epileptic Drug Market; Sales Growing Rapidly
November 19, 2012
-
REGULATORY CSIMC Subcommittee Eyes Price Cuts for Long-Listed Drugs with Slow Generic Penetration
November 16, 2012
-
REGULATORY CSIMC OKs Listing for 15 APIs/22 Products; Peak Sales Estimated at 32.6 Billion Yen for Lotriga
November 15, 2012
-
BUSINESS Japan’s 25 Major Drug Makers Log Contrasting Domestic Biz Results on Varying New Product Performances
November 14, 2012
-
REGULATORY Health Coverage for OTC-Like Drugs Up for Review Yet Again
November 13, 2012
-
REGULATORY Zoledronic Acid, Sildenafil Subject to Pilot Study on Generic RMPs
November 12, 2012
ページ
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…